CoDIFy Phase 2 Trial Data

23 November 2015

Ridinilazole (SMT19969) demonstrates statistical superiority over vancomycin in sustained clinical response in the treatment of C. difficile infection in CoDIFy, a Phase 2 proof of concept clinical trial.


Click to read the press release

Click to listen to a replay of the conference call

Click to read more about C. difficile infection.



Share Price

130.50p -1.00
at 06:15pm GMT 27 Nov 2015

$10.64 -0.01
at 05:10pm ET 27 Nov 2015

Current Programmes

  • C. Difficile Infections banner image

    C. difficile Infection

    Clostridium difficile infection (‘CDI’) is a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. It is a serious illness caused by infection of the colon by the bacteria, C. difficile, which produces toxins that cause inflammation, severe diarrhoea and can in the most serious of cases be fatal.

    Read More
  • Duchenne Muscular Dystrophy image boy

    Duchenne Muscular Dystrophy

    Duchenne Muscular Dystrophy (‘DMD’) is a fatal, genetic disease that predominantly affects boys. It has a population of around 50,000 in the developed world and is classified as a rare or orphan disease. DMD is caused by the absence of a protein called dystrophin which is essential in maintaining the healthy function of muscles in the body.

    Currently there is no disease modifying treatment for all patients with DMD.

    Read More